Pfizer's shares surged 1.5% as its respiratory syncytial virus (RSV) vaccine, Abrysvo, demonstrated positive results in a trial for high-risk adults under 60. The vaccine was well tolerated and produced immune responses similar to those seen in older adults.
The trial included 681 adults with conditions like asthma and diabetes. Pfizer plans to seek expanded approval for adults aged 18 to 59 based on these findings. RSV, a common cause of pneumonia, affects both toddlers and older adults. However, experts have differing views on the vaccine's clinical benefit for most individuals in these high-risk groups.
Opmerkingen